WHO concludes Pre-Qualification of Pentavalent Vaccine Easyfive-TT of Panacea Biotec

19 Sep 2013 Evaluate

World Health Organization (WHO) has completed the evaluation process of Pre-qualification (PQ) of its Pentavalent vaccine Easyfive-TT (DTwP-HepB-Hib). WHO has informed that they are initiating the arrangements for PQ, and has informed the UNICEF (the procurement agency for Global markets) of the positive outcome of the evaluation process. WHO will be issuing the letter to UNICEF informing the PQ of EasyfiveTT mono (1 dose) and multi-dose (10 dose) presentations and the details of PQ will also be published on WHO webpage soon. The Company has successfully completed the audit of its Lalru and Baddi facilities, conducted by WHO team from February, 28 till March, 1 2013.

The Company is preparing itself to supply Easyfive-TT vaccine (pentavalent vaccine that protects against five diseases - Diphtheria, Tetanus, Pertusis, Hepatitis B and Haemophilus influenzae type b (Hib) of early childhood) to UNICEF and other international agencies involved in procurement of vaccines at Global as well as National levels in various countries.

Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

143.25 -2.90 (-1.98%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.